BusinessMallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic EncephalopathyBy Nasdaq OMXNov 2, 2017, 10:56 AM UTC
BusinessOcera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®By Nasdaq OMXOct 20, 2017, 11:30 AM UTC
BusinessOcera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017By Nasdaq OMXAug 23, 2017, 1:05 PM UTC
BusinessOcera Therapeutics Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 1, 2017, 8:05 PM UTC
BusinessOcera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2By Nasdaq OMXMay 26, 2017, 1:05 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
